论文信息 - CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). - 字舞流文

CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).

D. Berry | C. Perou | E. Winer | C. Hudis | J. Bellon | Baljit Singh | L. Carey | D. Collyar | E. Mamounas | M. Polley | E. Port | A. Partridge | W. Sikov | G. Somlo | S. Tolaney | M. Golshan | Cynthia X. Ma | C. Kuzma | O. Hahn | E. Twohy